Abstract
IntroductionThere is extensive data on the safety and effectiveness of switching from originator infliximab to biosimilar infliximab. However, there is relatively little data regarding biosimilar-biosimilar infliximab switch nor on multiple...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
